Highly sensitive monoclonal antibody residual detection assay
View Patent ↗The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products.
1. A method for detecting an antibody product, or fragment thereof, the method comprising:
(a) contacting a test sample suspected of containing the antibody product or fragment thereof with a substrate comprising a mixture of five or more distinct classes of capture antibodies or antigen binding fragments thereof so as to form at least one capture antibody-antibody product complex;
wherein the five or more distinct classes of capture antibodies or antigen binding fragments thereof are: anti-human IgG heavy and light chains (H+L), anti-human IgG F(ab') 2 , anti-human IgG lambda, anti-human IgG kappa, and anti-mouse IgG (H+L) antibodies; and wherein the anti-human IgG (H+L), anti-human IgG F(ab′) 2 , anti-human IgG lambda, anti-human IgG kappa, and anti-mouse IgG (H+L) antibodies are present in the mixture in a ratio of 1:2:16:8:8;
(b) detecting the at least one capture antibody-antibody product complex using a composition capable of detecting the at least one capture antibody-antibody product complex, wherein detection of the at least one capture antibody-antibody product antigen-complex is indicative of the presence of the antibody product, or fragment thereof, in the test sample.
2. The method of claim 1 , wherein the composition capable of detecting the at least one capture antibody-antibody product complex is a labeled detection antibody capable of binding the at least one capture antibody-antibody product antigen complex.
3. The method of claim 1 , wherein the presence of antibody product, or fragment thereof, is indicative of product carry over.
4. The method of claim 1 , wherein an amount of the antibody product, or fragment thereof, is indicative of an effectiveness of a cleaning process.
5. The method of claim 1 , wherein the antibody product or fragment thereof is selected from the group consisting of: polyclonal antibodies; human monoclonal antibodies; humanized monoclonal antibodies; chimeric monoclonal antibodies; single chain antibodies; Fab antibody fragments; F(ab′) 2 antibody fragments; Fd antibody fragments; Fv antibody fragments; and diabodies.